Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3965079rdf:typepubmed:Citationlld:pubmed
pubmed-article:3965079lifeskim:mentionsumls-concept:C0025344lld:lifeskim
pubmed-article:3965079lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:3965079lifeskim:mentionsumls-concept:C0025149lld:lifeskim
pubmed-article:3965079lifeskim:mentionsumls-concept:C2347804lld:lifeskim
pubmed-article:3965079lifeskim:mentionsumls-concept:C1561960lld:lifeskim
pubmed-article:3965079lifeskim:mentionsumls-concept:C1709940lld:lifeskim
pubmed-article:3965079lifeskim:mentionsumls-concept:C1948053lld:lifeskim
pubmed-article:3965079pubmed:issue1lld:pubmed
pubmed-article:3965079pubmed:dateCreated1985-2-1lld:pubmed
pubmed-article:3965079pubmed:abstractTextCollins postulated that patients with Wilms' tumor surviving for a period equal to their age at diagnosis plus 9 months were no longer at risk for a recurrence. Although this no longer holds for Wilms' tumor, it has been applied to patients with medulloblastoma. Case histories of patients who survived a period of risk designated by Collins' rule and later developed a histologically confirmed recurrent medulloblastoma are discussed. Reported cases violating Collins' rule constitute less than 2% of all medulloblastomas. The continued use of Collins' rule is advocated. Patients who have survived this period of risk, are neurologically stable, and have a negative computerized tomography (CT) head scan are exceedingly unlikely to develop a recurrent medulloblastoma.lld:pubmed
pubmed-article:3965079pubmed:languageenglld:pubmed
pubmed-article:3965079pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3965079pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3965079pubmed:statusMEDLINElld:pubmed
pubmed-article:3965079pubmed:monthJanlld:pubmed
pubmed-article:3965079pubmed:issn0008-543Xlld:pubmed
pubmed-article:3965079pubmed:authorpubmed-author:HahnJ FJFlld:pubmed
pubmed-article:3965079pubmed:authorpubmed-author:MealeyJJJrlld:pubmed
pubmed-article:3965079pubmed:authorpubmed-author:HumphriesRRlld:pubmed
pubmed-article:3965079pubmed:authorpubmed-author:MoylanD JDJlld:pubmed
pubmed-article:3965079pubmed:authorpubmed-author:LatchawJ PJPlld:pubmed
pubmed-article:3965079pubmed:issnTypePrintlld:pubmed
pubmed-article:3965079pubmed:day1lld:pubmed
pubmed-article:3965079pubmed:volume55lld:pubmed
pubmed-article:3965079pubmed:ownerNLMlld:pubmed
pubmed-article:3965079pubmed:authorsCompleteYlld:pubmed
pubmed-article:3965079pubmed:pagination186-9lld:pubmed
pubmed-article:3965079pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:meshHeadingpubmed-meshheading:3965079-...lld:pubmed
pubmed-article:3965079pubmed:year1985lld:pubmed
pubmed-article:3965079pubmed:articleTitleMedulloblastoma. Period of risk reviewed.lld:pubmed
pubmed-article:3965079pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3965079pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965079lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3965079lld:pubmed